Quantcast
Channel: Physician's Weekly
Viewing all articles
Browse latest Browse all 3217

Sacituzumab Govitecan Shows Promise in Advanced Endometrial Cancer

$
0
0

WEDNESDAY, Aug. 14, 2024 (HealthDay News) — For patients with advanced endometrial cancer (EC), sacituzumab govitecan (SG), a trophoblast cell-surface antigen 2 (Trop-2)-directed antibody-drug conjugate, shows encouraging efficacy, according to a phase 2 study published online July 31 in the Journal of Clinical Oncology.

Alessandro D. Santin, M.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues conducted a phase 2 basket study to examine the efficacy and safety of SG in patients with advanced EC. Eligible patients received SG 10 mg/kg once on days 1 and 8 every three weeks; median follow-up was 5.8 months. The primary end point was the objective response rate.

Forty-one patients were enrolled at the data extraction date; the median previous therapies was three, and 85 percent of participants received previous chemotherapy and immunotherapy. The researchers found an objective response rate of 22 percent and a clinical benefit rate of 32 percent. The median duration of response was 8.8 months, and median progression-free survival was 4.8 months. For 39 patients, a Trop-2 exploratory analysis was conducted retrospectively. There was high expression of tumor Trop-2 protein in EC, with limited correlation seen with efficacy. Seventy-three percent of patients had grade ≥3 treatment-related adverse events (TRAEs). Discontinuation of study drugs due to TRAEs was 5 percent. There were two deaths, which were unrelated to SG.

“On the basis of the results from this trial, a randomized phase III study is planned,” the authors write.

Several authors disclosed ties to pharmaceutical companies, including Gilead Sciences, which manufactures sacituzumab govitecan and funded the study.

Abstract/Full Text

Copyright © 2024 HealthDay. All rights reserved.
healthday

The post Sacituzumab Govitecan Shows Promise in Advanced Endometrial Cancer first appeared on Physician's Weekly.


Viewing all articles
Browse latest Browse all 3217

Trending Articles